The pen needles market size in Europe was valued at USD 810 million in 2023. The Latin America is anticipated to progress at a CAGR of 10.04% from 2024 to 2029 and be worth USD 1.44 billion by 2029 from USD 0.89 billion in 2024.
Needle manufacturers have produced needles to reduce pain and diminish skin trauma, primarily by innovating needle length and diameter. The primary challenge for needle manufacturers is to keep a sufficient inner lumen while maintaining sufficient low injection force. Pen needles are used to administer the medication, such as insulin or other injectable medicines, combined with injection pens. A pen needle contains a hollow needle connected to an injection pen. Pen needles are prepared with various needle lengths and used by diabetes patients.
The growing rate of diabetic patients, the existence of favorable regulatory policies to reduce needlestick injuries, the growing focus on the utilization of safety equipment by the government, increasing funds for diabetes care & research in the U.K., and favorable reimbursement policies in Germany are accelerating the growth of pen needles market in Europe. Additionally, an increasingly aging population & availability of high insurance in France, a growing number of diabetes awareness programs in Italy, and the existence of regulations that mandate the utilization of safety pen needles & the presence of a substantial diabetic population in Spain are further driving the growth of the market in Europe.
The reusability of pen needles, complications associated with needle use, and availability of alternative dosage forms may hamper the region's market growth. Lack of knowledge among people on pen needles utilization and uncertain reimbursement policies across Europe are restraining the development of the pen needles market in Europe.
In this region, Germany is estimated to account for the largest share of the Europe pen needles market in 2023. In contrast, France is estimated to grow at the highest CAGR during the forecast period. Europe is expected to see an overall boost in the pen needles market due to the rising prevalence of its target disease. Moreover, the U.K. government is also taking initiatives to invest in diabetes care and research to improve diabetic patients' treatment techniques. Europe is projected to dominate the global market due to a rise in the prevalence of diabetes among all ages, technological advancements, and an increase in research and development activities on diabetes care. This dominance may also be due to a rise in overweight & obesity, unhealthy diet, and physical inactivity.
Companies that play a promising role in the Europe pen needles market include Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.a., HTL-STREFA S.A. and Terumo Corporation.
By Therapy
By Type
By Needle Length
By Mode of Purchase
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region